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Abstract: AIM To evaluate the frequency of loss of mediator of DNA damage checkpoint protein 1
(MDC1) protein expression in endometrial cancer (EC) and to determine whether loss of MDC1 is as-
sociated with certain clinicopathological parameters. MATERIALS AND METHODS MDC1 expression
was examined in 426 samples of EC. The nuclear immunoreactivity of the protein was defined as: negative,
weak, moderate and strong. RESULTS Loss of MDC1 expression (defined as negative nuclear staining)
was found in 8.9% (38/426) of ECs and was significantly associated with the loss of MRE11 homolog,
double-strand break repair nuclease, RAD50 double-strand break repair protein and nibrin complex com-
ponents. In addition, loss of expression of MDC1 showed a significant correlation with any mismatch
repair deficiency, with endometrioid histological subtype and low tumour grading. CONCLUSION Based
on these findings, we suggest that MDC1 loss frequently occurs in ECs with microsatellite instability.
Due to deficient homologous recombination DNA repair, MDC1-negative ECs might show an increased
sensitivity to poly(ADP-ribose) polymerase-inhibitory therapy.
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Abstract. Aim: To evaluate the frequency of loss of
mediator of DNA damage checkpoint protein 1 (MDC1)
protein expression in endometrial cancer (EC) and to
determine whether loss of MDC1 is associated with certain
clinicopathological parameters. Materials and Methods:
MDC1 expression was examined in 426 samples of EC. The
nuclear immunoreactivity of the protein was defined as:
negative, weak moderate and strong. Results: Loss of MDC1
expression (defined as negative nuclear staining) was found
in 8.9% (38/426) of ECs and was significantly associated
with the loss of MRE11 homolog, double-strand break repair
nuclease, RAD50 double-strand break repair protein and
nibrin complex components. In addition, loss of expression
of MDC1 showed a significant correlation with any
mismatch repair deficiency, with endometrioid histological
subtype and low tumour grading. Conclusion: Based on
these findings, we suggest that MDC1 loss frequently occurs
in ECs with microsatellite instability. Due to deficient
homologous recombination DNA repair, MDC1-negative ECs
might show an increased sensitivity to poly(ADP-ribose)
polymerase-inhibitory therapy.
Endometrial cancer (EC) is the most common gynecologic
carcinoma in developed countries and the fourth most
common neoplasm among women worldwide (1, 2). The vast
majority presents at an early stage (75%) (3) with a relatively
favourable prognosis (4). Treatment options, however, for
advanced, recurrent or metastatic ECs, are limited and
consist mainly of cytotoxic chemotherapy. There are a large
number of gene abnormalities as well as aberrant signaling
pathways such as phosphatidylinositol-4,5-bisphosphate 3-
kinase catalytic subunit alpha (PIK3CA)/ phosphatase and
tensin homolog (PTEN)/AKT serine/threonine kinase (AKT)/
mechanistic target of rapamycin kinase (mTOR) that appear
to be promising targets but clinical studies are lacking.
Recently, potential targeted treatments such as the immune
checkpoint inhibitor pembrolizumab in patients with
microsatellite instability (MSI)-high EC have been
incorporated in clinical use (5, 6). 
ECs are classified into two types based upon
clinicopathological features and their clinical prognosis (7-
9). Type I neoplasms are low-grade endometrioid ECs (10).
They are stimulated by estrogens, patients present with them
at an early stage and have a good prognosis (11).
Endometrioid type accounts for the majority of ECs (90%)
(12). Type II neoplasms are grade 3 endometrioid ECs and
non-endometrioid tumours such as serous or clear cell
carcinoma (12, 13). In addition, these two categories are
characterized by their specific molecular aberrations which
occur preferentially either in type I or type II ECs (9). Type
I cancer harbours MSI as well as polymutations in different
types of genes whereas p53 mutations occur more common
in type II ECs (14, 15). 
Studies from the Cancer Genome Atlas classified 373 ECs
into four genomic subtypes based upon their copy-number
changes and genomic profile: DNA polymerase epsilon
(POLE) ultramutated, MSI hypermutated, copy-number-low
and the copy-number-high subgroups (16). The hypermutated
subtype includes mostly endometrioid ECs, all harbouring
MSI (16). These types of cancer are known to harbour
mutations in other different genes (hypermutated genome)
such as those participating in the DNA double-strand break
repair mechanisms (17).
In the past few years, molecular-targeted cancer therapies
have been developed, making use of the phenomenon of
synthetic lethality (18). Nearly a hundred years ago, Bridges
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first described the concept of synthetic lethality (19).
Synthetic lethality between two genes arises when an
alteration in the expression of either of them leads to a
phenotype that is compatible with viability, whereas
concurrent inhibition of both genes causes cell death (20).
To implement this idea, cancers incorporating a synthetic
lethal mutation have to be identified in order to target the
synthetic lethal partner gene. One of the most beneficial
features of such a specific anticancer drug is that it does not
affect healthy tissue (21).
Recently, it was postulated that cancer cells which harbour
deficiency of homologous recombination (HR) DNA-repair
mechanisms have an increased sensitivity to poly(ADP-
ribose) polymerase (PARP) inhibitors (22, 23). Inhibition of
PARP1 enzymatic activity leads to an accumulation of
single-strand breaks that are converted to double-strand
breaks but cannot be repaired by HR. Inhibition of PARP has
therefore been advanced as a novel targeted therapy for
cancers harbouring breast cancer 1/2 (BRCA1/2) mutations
(24). One of the most common mutations is found in the
MRE11 homolog, double-strand break repair nuclease
(MRE11), whose product is a part of the MRE11–RAD50
double-strand break repair protein (RAD50)–nibrin (NBN)
(MRN) complex that is involved in the detection and repair
of DNA double-strand breaks (25, 26). In a previous report
we showed that not only the expression of MRE11 but also
the expression of the other MRN complex components
RAD50 and NBN is lost in 30.7% of ECs. Furthermore, we
observed a significant association between loss of MRN
components and mismatch repair (MMR) status in ECs. A
decrease in MRE11 expression and function led to increased
sensitivity towards PARP inhibition in EC cell lines (22).
Recent studies have shown that mediator of DNA damage
checkpoint protein 1 (MDC1) is a participant in the early
response to DNA damage and its subsequent signaling within
cells. Its co-localization with BRCA1 is suggestive of a role
in homologous recombination.
MDC1 plays an important role in the DNA double-strand
break repair machinery by being part of two important DNA
repair pathways: the non-homologous end-joining response
and HR (27, 28). The aim of the study was to evaluate the
frequency of loss of MDC1 protein expression in ECs and to
examine whether loss of MDC1 is associated with
clinicopathological features and MMR protein status in EC. 
Materials and Methods
EC sample characteristics. Tissue microarrays (TMAs) of formalin-
fixed and paraffin-embedded ECs were assembled as previously
published (22, 29), containing samples of two cohorts from the
Institutes of Surgical Pathology, University Hospital Basel and
Zurich (Switzerland), containing 339 (Basel-TMA) and 182 (Zurich-
TMA) cancer samples in total. The study was approved for both
cohorts by the local Scientific Ethics Committee (KEK-ZH-NR:
2010-0358). In the present study, a total of 426 EC samples were
available for further analysis due to tissue loss in some TMA spots.
Clinical and pathological characteristics were taken from the clinical
databases and pathology records. Routine hematoxylin and eosin
sections were performed for histopathological evaluation. The stage
of tumours was assessed according to the International Federation
of Gynaecology and Obstetrics (FIGO) and TNM staging system.
Histological subtype and tumour grade were defined according to
the WHO classification 2014. Follow-up data are known from 480
patients. The median follow-up time was 31.5 (range=1-184)
months for the Basel cohort, and 45 (range=1-124) months for the
Zurich cohort. Baseline characteristics of patients with endometrial
cancer are summarized in Table I.
Immunohistochemistry. After antigen retrieval, the slides were
incubated with an antibody against MDC1 for 1 hour at room
temperature. The antibodies against MDC1 (rabbit polyclonal,
1:250) were obtained from Bethyl Laboratories (Montgomery, TX,
USA) and LubioScience (Zurich, Switzerland). The staining was
conducted with a Ventana Benchmark automated system (Ventana
Medical Systems, Tucson, AZ, USA) using Ventana reagents as well
as UltraMap™ DAB detection kit (Ventana Medical Systems,
Tucson, AZ, USA). The microscopic analysis of the staining was
independently performed by two pathologists (SB, AN). We
observed nuclear immunoreactivity of MDC1 and scored the
intensity of nuclear expression as following: Negative, weak,
moderate and strong. The protein expression of the MMR genes was
considered as positive when nuclear staining was evident and
negative when complete loss of nuclear staining was observed.
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Table I. Clinical characteristics of patients with endometrial carcinoma.
Variable                                                                             n (%)
Age at diagnosis
   ≤68 Years                                                                   218 (52.3)
   >68 Years                                                                  199 (47.7)
   Unknown                                                                       9 (2.1)
FIGO stage
   I                                                                                  213 (50.0)
   II                                                                                  54 (12.7)
   III                                                                                 70 (16.4)
   IV                                                                                 14 (3.3)
   Unknown                                                                     75 (17.6)
Histological subtype
   Endometrioid                                                             355 (83.3)
   Mucinous                                                                       3 (0.7)
   Serous                                                                          31 (7.3)
   Clear cell                                                                     14 (3.3)
   Carcinosarcoma/MMMT                                            13 (3.1)
   Undifferentiated                                                          10 (2.3)
   Endometrioid (incl. mucinous)                                358 (84)
   Non-endometrioid                                                       68 (16)
Grading
   1 & 2                                                                         312 (73.2)
   3                                                                                 114 (26.8)
FIGO: Fédération Internationale de Gynécologie et d’Obstétrique;
MMMT: malignant mixed Müllerian tumor.
Stromal cells showing nuclear staining were used as a positive
control.
Statistical analysis. The statistical evaluation was performed with
SPSS software Version 21.0 (IBM, Armonk, NY, USA). The scoring
data of MDC1 were dichotomized into negative (no expression) and
positive (any expression, weak to strong). The statistical significance
of the association with MMR protein expression, MRE11, RAD50,
and NBN, as well as clinicopathological parameters, was assessed
by chi-squared test for trends and Fisher’s exact test. Differences in
survival curves were compared by the log-rank test. Generally, p-
values of less than 0.05 were considered as significant. 
Results
MDC1 protein expression. Immunohistochemical analysis of
MDC1 of a total of 426 EC samples was performed.
Representative images of the different expression patterns
are shown in Figure 1. We found 38 negative cases, 85 weak
positive, 203 moderate and 100 strong positive cases. The
results were further grouped into negative and positive
staining. A total of 388 (91.1%) EC samples showed positive
staining for MDC1, 38 (8.9%) showed no nuclear
immunoreactivity. 
Association of MDC1 with clinicopathological characteristics.
MDC1 negative cases were significantly associated with the
endometrioid subtype (including mucinous) as compared with
the non-endometrioid subtype (serous, clear-cell, carcino-
sarcoma and undifferentiated) (p=0.018) and occurred more
often in grade 1 and 2 tumours than in grade 3 tumours
(p=0.02) as shown in Table II. No association with FIGO stage
or patient age was observed. 
Association of MDC1 with MMR protein status and MRN
complex proteins. In a previous study, we investigated MMR
protein status mutL homolog 1 (MLH1), mutS homolog 2
(MSH2), mutS homolog 6 (MSH6), PMS1 homolog 2,
mismatch repair system component (PMS2) and MRN
complex proteins like MRE11, RAD50, and NBN in this EC
cohort (22). Since MDC1 plays a role in DNA repair, we
were interested in looking for an association between MDC1
and MMR, as well as MRN status. The expression of MMR
proteins was considered as positive when nuclear staining
was evident. Stromal cells showing nuclear staining were
used as a positive control. MMR deficiency was defined as
negative nuclear staining for any of the evaluated MMR
proteins (MLH1, PMS2, MSH2 or MSH6). Negativity for
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Figure 1. Expression of mediator of DNA damage checkpoint 1 (MDC1) protein in endometrial carcinomas as assessed by immunohistochemistry
(magnification: ×20). 0: Negative (complete loss of MDC1 protein expression). 1: Weak nuclear expression. 2: Moderate nuclear expression. 3:
Strong nuclear expression. Representative images are shown.
MDC1 was more frequently observed in carcinomas with
MMR deficiency (n=27, p=0.0001). 
Furthermore, an association of carcinomas with negative
MDC1 immunohistochemistry and loss of nuclear protein
expression of the evaluated MRN complex proteins MRE11
(n=25, p=0.0001), RAD50 (n=16, p=0.007) and NBS1
(n=29, p=0.0001) were demonstrated (shown in Table III). 
MDC1 expression and impact on overall survival in patients
with ECs. In univariate Kaplan–Meier analysis, FIGO stage,
histological subtype, grading and patient age were prognostic
factors for overall survival (log-rank, p<0.0001 for all
parameters). However, the expression of MDC1 (log rank,
p=0.110) was not associated with overall survival.
Discussion
Cells are continuously exposed to agents that lead to DNA
damage, which, if not repaired effectively and efficiently, can
result in genomic instability. The HR pathway plays an
important role in this context. HR-deficient tumours have
been reported widely in literature, including ovarian and
breast cancer (30, 31).
In mice, mutation of Mdc1 causes impaired spermatogenesis,
as well as other disorders due to genomic instability (32).
Because of its role as a potential tumour suppressor, loss of
MDC1 expression has been described in various types of
neoplasms such as breast, lung (33) and gastric carcinoma (34).
Besides being part of HR (14, 15), MDC1 contributes to the
DNA damage-response pathway by managing the activation of
the intra-S-phase and G2/M phase cell-cycle checkpoints in the
case of DNA damage (35, 36). After exposure of cells to
ionizing radiation and other factors as UV irradiation and
endogenous damage, MDC1 mediates the recruitment of several
DNA-repair proteins to the site of damaged DNA. These DNA
damage-induced foci involve other important proteins such as
tumour protein p53 binding protein 1 (TP53BP1), BRCA1 and
the heterotrimeric MRN complex (37). 
To our knowledge, this is the first report to show the role
of MDC1 protein in samples of human EC. Our studies show
that the expression of MDC1 protein is lost in a notable
proportion of ECs (8.9%). In a previous study, we
investigated the MMR protein status (MLH1, MSH2, MSH6,
PMS2) and MRN complex proteins MRE11, RAD50, and
NBS in this EC cohort (22). Since MDC1 plays a role in
DNA repair, we were interested in an association between
MDC1 and MMR, as well as MRN status. We observed an
association between loss of MDC1 and MMR protein
deficiency as well as loss of nuclear protein expression of
the evaluated MRN complex proteins which suggests that
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Table II. Immunohistochemical expression of mediator of DNA damage
checkpoint 1 (MDC1), MRE11 homolog, double-strand break repair
nuclease (MRE11), RAD50 double-strand break repair protein (RAD50),
nibrin (NBN) mismatch-repair (MMR) proteins.
Marker                                                    Expression                   n (%)
MDC1 (n=426)                                      Negative                    38 (8.9)
                                                               Positive                   388 (91.1)
MRN complex (n=414)                         Negative                  167 (40.3)
                                                               Positive                   247 (59.7)
MRE11 (n=415)                                    Negative                  132 (31.8)
                                                               Positive                   283 (68.2)
RAD50 (n=419)                                    Negative                  101 (24.1)
                                                               Positive                   318 (75.9)
NBN (n=416)                                         Negative                  127 (30.5)
                                                               Positive                   289 (69.5)
Any MMR deficiency (n=391)             Negative                  178 (45.5)
                                                               Positive                   213 (54.5)
Table III. Association of expression of mediator of DNA damage
checkpoint 1 (MDC1) with clinicopathological features, and
components of the MRE11 homolog, double-strand break repair
nuclease (MRE11)–RAD50 double-strand break repair protein
(RAD50)–nibrin (NBN) (MRN) complex.
                                                                        MDC1, n
Variable                                               Negative        Positive       p-Value
Histological subtype
   Endometrioid                                         37                318             0.25
   Mucinous                                                 0                     3               
   Serous                                                       0                   31               
   Clear cell                                                  1                   13               
   Carcinosarcoma/MMMT                         0                   13               
   Undifferentiated                                       0                   10               
   Endometrioid (incl. mucinous)             37                321             0.018
   Non-endometrioid                                    1                   67               
Grade
   1 & 2                                                      34                278             0.02
   3                                                                4                 110               
Any MMR deficiency
   Negative                                                 27                151          <0.0001
   Positive                                                  10                203               
MRE11
   Negative                                                 25                107          <0.0001
   Positive                                                   11                272               
RAD50
   Negative                                                 16                  85             0.007
   Positive                                                  20                298               
NBN
   Negative                                                 29                  98          <0.0001
   Positive                                                    7                282               
MRN complex
   Negative                                                 30                137          <0.0001
   Positive                                                    6                241               
MMMT: Malignant mixed Müllerian tumor; MMR: mismatch repair. 
MDC1 loss is a frequent occurrence in MMR-deficient ECs
(hypermutated subgroup). 
Previous studies verified that tumour cells with impaired
HR DNA-repair exhibit increased sensitivity to PARP
inhibitors. The therapeutic benefit of PARP inhibitors in
germline BRCA1/2-deficient tumours, such as breast,
ovarian, pancreatic and prostate cancers has been proven in
vitro as well as in clinical trials (38-41). For EC, the
synthetic lethal interaction between MRE11 and PARP1, was
demonstrated in vitro with PARP inhibitors (22).
Furthermore, the loss of PTEN, which is the most commonly
affected gene in endometrioid ECs (42), sensitizes cancer
cell lines to PARP-inhibitory treatment (43) although the
exact function of PTEN in homologous recombination is not
clearly defined. Various studies have suggested that loss of
MDC1 might be associated with a favourable prognosis.
Recently, Wang et al. showed that MDC1-depletion
combined with PARP inhibition can enhance the sensitivity
of olaparib in nasopharyngeal carcinoma. MDC1-deficient
cells also revealed a decrease of BRCA1, BRCA2 and
RAD51, which is suggestive of a direct inhibit of HR-
mediated DNS repair through impairment of neighboring
foci. The down-regulation of MDC1 led to defective HR
through blockage of DNA damage-repair proteins (44). 
Based on these findings, we conclude that loss of MDC1
expression occurs in a notable proportion of ECs, is more
common in low-grade endometrioid EC than in non-
endometrioid EC, and is associated with MMR deficiency.
Due to deficient HR DNA repair, we postulate that tumours
with loss of MDC1 might have increased sensitivity to PARP
inhibitor therapy. The effect of MDC1-negative ECs on
sensitivity to PARP inhibitor in EC has not yet been proven
and needs further investigation. 
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